uniQure N.V. (NASDAQ:QURE) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of uniQure N.V. (NASDAQ:QURE) have been given a consensus recommendation of “Moderate Buy” by the seventeen analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and twelve have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $64.1667.

QURE has been the topic of a number of research reports. Barclays raised uniQure from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $25.00 to $65.00 in a research note on Thursday, June 18th. Stifel Nicolaus set a $28.00 price target on shares of uniQure in a report on Tuesday, May 5th. Chardan Capital lifted their price objective on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price objective on the stock in a research note on Wednesday, June 17th. Finally, Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th.

Insider Transactions at uniQure

In other uniQure news, insider Walid Abi-Saab sold 45,000 shares of the business’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $25.06, for a total transaction of $1,127,700.00. Following the sale, the insider owned 169,669 shares in the company, valued at approximately $4,251,905.14. The trade was a 20.96% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Madhavan Balachandran sold 11,685 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total transaction of $526,526.10. Following the completion of the sale, the director owned 43,254 shares of the company’s stock, valued at approximately $1,949,025.24. This trade represents a 21.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 433,229 shares of company stock valued at $17,944,799 in the last 90 days. 4.65% of the stock is owned by corporate insiders.

Institutional Trading of uniQure

Several hedge funds and other institutional investors have recently modified their holdings of QURE. China Universal Asset Management Co. Ltd. lifted its stake in shares of uniQure by 5.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock valued at $243,000 after buying an additional 533 shares during the period. Arizona State Retirement System increased its position in shares of uniQure by 6.0% during the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after purchasing an additional 627 shares during the period. Ensign Peak Advisors Inc raised its stake in shares of uniQure by 21.7% in the fourth quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 650 shares in the last quarter. FNY Investment Advisers LLC raised its stake in shares of uniQure by 76.7% in the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 718 shares in the last quarter. Finally, CIBC Private Wealth Group LLC bought a new position in uniQure in the third quarter worth $50,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Stock Performance

QURE stock opened at $40.25 on Monday. The company has a market capitalization of $2.54 billion, a P/E ratio of -11.57 and a beta of 0.90. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. The company has a 50-day simple moving average of $34.78 and a 200 day simple moving average of $25.11. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $71.50.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. Sell-side analysts predict that uniQure will post -3.56 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.